Subscribe
Business

Elan, Biogen change terms of Tysabri collaboration

By The Associated Press
Published
Add Washington Examiner on Google

Biogen Idec will take over full ownership of the multiple sclerosis treatment Tysabri from its partner Irish drugmaker Elan Corp. PLC in exchange for a $3.25 billion cash payment and royalties on future sales.

The drug developers currently split earnings from Tysabri, but Elan said the new deal will give it capital for investing and growing its business.

Print subscriber? Click here to login/register your account
Digital subscriber? Click here to login/register your account.

Full midterm coverage.Deeper analysis.

Get unlimited access to Washington Examiner's reporting, expert analysis, and coverage of the midterm elections.

Get Unlimited Access

Cancel anytime.